title: Does nebivolol prevent contrast-induced nephropathy in humans?
abstract: BACKGROUND
  An experimental study showed that nebivolol is an effective agent in contrast-induced nephropathy (CIN) prophylaxis.
  
  
  OBJECTIVE
  We hypothesized that prophylactic nebivolol use had protective effects on renal function in human beings subjected to iodinated contrast agent since it has vasodilatory effect and antioxidant properties.
  
  
  METHODS
  The present study enrolled 120 patients scheduled for coronary angiography and ventriculography. All patients were hydrated with intravenous isotonic saline. The patients in group I received 600 mg N-acetylcysteine every 12 hours for 4 days. The patients in group II received 5 mg nebivolol every 24 hours for 4 days. The patients in group III were only hydrated. The primary endpoint was the occurrence of CIN. The secondary endpoint was the change in serum creatinine (Cr) levels at 2 days and 5 days after the contrast exposure.
  
  
  RESULTS
  Nine (22.5%) patients in group I developed CIN, as did 8 patients (20.0%) in group II and 11 patients (27.5%) in group III (P = 0.72). Changes in mean Cr level from baseline to day 2 were not statistically significant in all groups. However, we detected a statistically significant increase in mean Cr levels at day 5 compared with baseline levels in group I and group III (from 1.42 ± 0.13 to 1.52 ± 0.26, p2 = 0.02; and from 1.43 ± 0.14 to 1.55 ± 0.30, p2 = 0.01, respectively). Although an increase was detected in mean Cr level from baseline to the 5-day Cr level in group II, this did not reach statistical significance (from 1.40 ± 0.12 to 1.48 ± 0.23, P = 0.06).
  
  
  CONCLUSIONS
  Pretreatment with nebivolol is protective against nephrotoxic effects of contrast media.
authors.affiliation: Department of Cardiology, Erciyes University School of Medicine, Kayseri, Turkey. drgunebakmaz@yahoo.com
authors.forename: Ozgür
authors.initials: O
authors.lastname: Günebakmaz
authors.forename: Mehmet G
authors.initials: MG
authors.lastname: Kaya
authors.forename: Fatih
authors.initials: F
authors.lastname: Koc
authors.forename: Mahmut
authors.initials: M
authors.lastname: Akpek
authors.forename: Ahmet
authors.initials: A
authors.lastname: Kasapkara
authors.forename: M Tugrul
authors.initials: MT
authors.lastname: Inanc
authors.forename: Mikail
authors.initials: M
authors.lastname: Yarlioglues
authors.forename: Bekir
authors.initials: B
authors.lastname: Calapkorur
authors.forename: Zakir
authors.initials: Z
authors.lastname: Karadag
authors.forename: Abdurrahman
authors.initials: A
authors.lastname: Oguzhan
mesh_terms: D000111:Acetylcysteine / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000368:Aged; D000704:Analysis of Variance; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001578:Benzopyrans / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D003287:Contrast Media; D003404:Creatinine; D004983:Ethanolamines / Q000627:therapeutic use*; D005260:Female; D016166:Free Radical Scavengers / Q000627:therapeutic use; D006305:Health Status Indicators; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D000068577:Nebivolol; D011300:Preoperative Care / Q000379:methods*; D018570:Risk Assessment; D013223:Statistics as Topic; D014661:Vasoconstriction / Q000187:drug effects
chemical_list: D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D001578:Benzopyrans; D003287:Contrast Media; D004983:Ethanolamines; D016166:Free Radical Scavengers; D000068577:Nebivolol; D003404:Creatinine; D000111:Acetylcysteine